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Abstract. Colorectal cancer (CRC), which is one of the most 
common malignancies worldwide, results from an accumula-
tion of genetic and epigenetic modifications including DNA 
methylation. Neurotensin (NTS), a hormone localized to the 
gut and central nervous system, mediates its physiological and 
pathological effects, including growth stimulation for a variety 
of cancers, through three distinct NTS receptors (NTSRs). 
Most NTS functions are mediated through the high-affinity 
receptor NTSR1, and expression of NTSR1 is increased in 
many cancers including CRC. In this study, we investigated 
the expression profiles and cellular functions of the NTSRs, 
especially NTSR1, in CRC cells. We showed that expression 
levels for NTS and NTSR1 varied, that NTSR2 expression was 
not detectable and that NTSR3 was consistently expressed 
in all CRC cell lines examined. Treatment with the demeth-
ylating agent, 5-aza-2'-deoxycytidine, augmented levels of 
NTSR1/2 in Caco2 and DLD1 cells, which have little or no 
transcripts for NTSR1/2 suggesting that DNA methylation 
suppresses NTSR1/2 expression. In addition, we demon-
strated that knockdown of NTSR1 decreased cell growth and 
migration in HCT116 and HT29 cells. Finally, we showed 
that treatment with SR48692, an antagonist of NTSR1, also 
inhibited cell proliferation and migration in the CRC cells. 
Our findings identify promoter methylation as an important 
process regulating the differential expression or silencing 
of NTSR1/2 in CRC cells. Moreover, inhibition of NTSR1 
repressed tumorigenic effects in CRC cells, suggesting that 
NTSR1 may be used as a therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is one of the most common malig-
nancies in the United States and worldwide (1). Genetic 
alterations, specifically gene mutations implicated in CRC 
tumorigenesis, lead to a gain of oncogene function and loss of 
tumor suppressor gene function (2). Epigenetic modifications, 
particularly DNA methylation in selected gene promoters, 
are also recognized common molecular alterations in human 
tumors (2,3).
Neurotensin (NTS), a tridecapeptide mainly distributed 
along the gastrointestinal (GI) tract, functions to decrease 
gastric motility, to increase pancreaticobiliary secretion, to 
facilitate fatty acid absorption, and to increase proliferation 
of normal intestinal mucosa (4-6). In addition to these physi-
ologic effects, NTS influences intestinal inflammation and 
promotes the growth of cancers, including breast, prostate, 
pancreas, lung and cancers of the GI tract (4,7,8). The effects of 
NTS are exerted primarily by its G protein-coupled receptors: 
the high-affinity NTS receptor 1 (NTSR1), and the low-
affinity NTSR2 (7,8). NTSR3/sortilin, a single transmembrane 
receptor, also binds NTS and contributes to the diversity of 
effects on multiple tissues (7,8).
The properties of NTS are predominantly mediated 
through NTSR1, and this neuropeptide-receptor complex 
is deregulated during cancer progression (8,9). Although 
increased expression of NTSR1 has been identified in certain 
cancer types, such as colon and neuroendocrine tumors 
(NETs) (10-16), the molecular mechanisms regulating NTSRs 
expression have not been clarified. Recently, we reported that 
promoter methylation is an important molecular process that 
regulates the differential expression of NTSR1 and silences 
NTSR2 in NET cells, and that silencing of NTSR1 suppressed 
the oncogenic effects of NTS (16). In the current study, we 
analyzed the endogenous expression of NTS signaling 
components, the transcriptional change of NTSR genes medi-
ated by a demethylating agent, and the methylation status of 
their promoters in CRC cell lines. Importantly, we show that 
inhibition of NTSR1 by either gene knockdown or treatment 
with an NTSR1 inhibitor decreases the growth and migration 
of CRC cells.
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Materials and methods
Cell lines, reagents and siRNA transfection. The human 
CRC cell lines KM12c, Caco2, DLD1, HT29, HCT116, 
and SW480 were used in these studies. Cell lines were 
authenticated in february and May 2016 at genetica DNA 
Laboratories (Cincinnati, OH). KM12c cells were kindly 
provided by Dr isaiah J. fidler (M.D. Anderson Cancer 
Center, Houston, TX, USA); other cell lines were obtained 
from American Type Culture Collection (Manassas, vA, 
USA). KM12c cells were cultured in MEM supplemented 
with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 
1% non-essential amino acids and 2% MEM essential vita-
mins. Caco2 cells were incubated in MEM supplemented 
with 15% FBS, 1% sodium pyruvate and 1% non-essential 
amino acids. DLD1 cells were grown in RpMi-1640 with 
10% FBS. HT29 and HCT116 cells were maintained in 
McCoy's 5A medium supplemented with 10% FBS. SW480 
cells were cultured in DMEM with 10% fBS. Cells were 
maintained at 37˚C in a humidified 5% CO2 incubator. The 
DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine 
(5-aza-CdR), and a selective inhibitor for NTSR1, SR48692, 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and dissolved in dimethyl sulfoxide (DMSO). Transfections 
with non-targeting control and SMARTPool NTSR1 siRNA 
(Dharmacon, Lafayette, CO, USA) were performed using 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) 
as previously described (16).
RNA isolation, reverse transcription-PCR (RT-PCR) and 
quantitative reverse transcription-PCR (RT-qPCR) analysis. 
Total RNA isolation, cDNA synthesis and RT-pCR analysis 
were carried out as previously described (16,17). Briefly, 
RT-PCR reactions for NTS signaling elements were performed 
using cDNA synthesized from 1 µg of total RNA from CRC 
cells, HotStarTaq DNA polymerase (Qiagen, Valencia, CA, 
USA) and primers as follows: NTSR1 F, 5'-TCATCGC 
CTTTGTGGTCTGCT-3', and NTSR1 R, 5'-TGGTTGCT 
GGACACGCTGTCG-3', 33 cycles; NTSR2 F, 5'-GTCTCC 
TCAGCTTCATCGTAT-3', and NTSR2 R, 5'-TCCCCAA 
AGCCTGAAGCTGTA-3', 40 cycles; NTSR3 F, 5'-AGAA 
TGGTCGAGACTATGTTG-3', and NTSR3 R, 5'-AAG 
AGCTATTCCAAGAGGTCC-5', 33 cycles; NTS F, 5'-GAT 
GATGGCAGGAATGAAAATCCAG-3', and NTS R, 5'-GTT
GAAAAGCCCTGCTGTGACAGA-3', 40 cycles; β-actin 
F, 5'-TCACCAACTGGGACGACATG-3', and β-actin 
R, 5'-ACCGGAGTCCATCACGATG-3', 28 cycles; IL-8 
F, 5'-CATGACTTCCAAGCTGGCCG-3', and IL-8 R, 5'-AAT
TTTTTTATGAATTCTCAGCCCTC-3', 33 cycles; cyclin D1 
F, 5'-ATGTGTGCAGAAGGAGGTCC-3' and cyclin D1 
R, 5'-CTTAGAGGCCACGAACATGC-3', 38 cycles. Cycling 
conditions for the reactions were: initial melting at 95˚C for 
15 min, followed by the above described numbers of cycles at 
94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 45 sec and a final 
extension of 10 min at 72˚C (MJ Mini Thermal Cycler, 
Bio-Rad, Irvine, CA, USA). The PCR products were analyzed 
on a 2% agarose gel and visualized with the Alpha Innotech 
Imaging system (Alpha Innotech Corp., San Leandro, CA, 
USA). RT-qPCR was carried out using TaqMan kits (Applied 
Biosystems, Foster City, CA, USA) under StepOnePlus 
Real-Time PCR System (Applied Biosystems) as previously 
described (16), according to the manufacturer's protocol.
Methylation analysis. The methylation status of the NTSR1 
and NTSR2 promoters was determined by methylation-specific 
pCR (MSp) and bisulfite sequencing (BS) analyses as previ-
ously described (16,17). In brief, PCR with 35 cycling reactions 
was performed using bisulfite-modified genomic DNA, 
HotStarTaq DNA polymerase (Qiagen) and primers as follows: 
NTSR1 MSP methyl (M) F, 5'-TTGGAATTCGTGGTA 
AGC-3', and NTSR1 MSP M R, 5'-GTCTCAAACGAAA 
ACCGATA-3'; NTSR1 MSP unmethyl (U) F, 5'-TATTTG 
GAATTTGTGGTAAGT-3', and NTSR1 MSP U R, 5'-ATCT 
CAAACAAAAACCAATAAAC-3'; NTSR2  MSP M 
F, 5'-GTGGAGTTCGGTTTAATTC-3', and NTSR2 MSP M 
R 5'-ACTACCCGAAATCTAAACG-3'; NTSR2 MSP U 
F, 5'-GGTGGAGTTTGGTTTAATTT-3', and NTSR2 MSP U 
R, 5'-CACTACCCAAAATCTAAACA-5'; NTSR1 BS 
F, 5'-TTGTGGATATTTAGGAGTGGG-3' and NTSR1 BS 
R, 5'-CTCCAAAAAACCAAAATTCC-3'; NTSR2 BS 
F, 5'-TGTTGGGAAAGTTTTTTTTAAG-3' and NTSR2 BS 
R, 5'-AAACACCTCCTCTTCTCTAAAAA-3'. The PCR 
products for MSP were visualized as indicated above. For BS, 
PCR products were cloned into the TOPO TA cloning vector 
(Invitrogen) and the plasmids from individual bacterial colo-
nies were sequenced.
Cell proliferation. Equal numbers of HCT116 and HT29 cells 
were seeded in 24-well plates. Proliferation of cells transfected 
with siRNA or treated with SR48692 was assessed at 48 and 
96 h after seeding by direct cell counting using a Beckman 
Coulter Cell viability Analyzer (Beckman-Coulter, Fullerton, 
CA, USA).
Western blot analysis. Western blot analysis was done as 
previously described (16). The antibodies for rabbit polyclonal 
NTSR1 (PA3-214, 1:2500 dilution) and rabbit monoclonal 
cyclin D1 (2261-1, 1:5000 dilution) were purchased from 
Thermo fisher Scientific (Rockford, iL, USA) and Epitomics 
(Burlingame, CA), respectively. The rabbit polyclonal IL-8 
(ab106350, 1:500 dilution) and mouse monoclonal anti-β-actin 
(A5316, 1:5000 dilution) antibodies were obtained from Abcam 
(Cambridge, MA, USA) and Sigma-Aldrich, respectively.
Wound-healing migration assay. A wound-healing migration 
assay was performed, using the Ibidi Culture Insert (Ibidi, 
Munich, Germany), with control and NTSR1 knockdown 
HCT116 or HT29 cells. The wounded monolayers, generated 
by removal of the insert, which provides a cell-free gap, were 
maintained for the indicated time periods. Phase-contrast 
microscopic images were acquired using a Nikon Eclipse Ti 
microscope and NIS Elements software (Nikon, Melville, NY, 
USA). The data are the quantified gap distance.
Luciferase reporter assays. HCT116 and HT29 cells, seeded 
in 24-well plates, were transiently transfected with the IL-8 
reporter (0.4 µg) and the Renilla luciferase reporter (0.05 µg) 
using Lipofectamine 2000 (Invitrogen) according to the 
manufacturers' instructions. For the NTSR1 inhibitor treat-
ments, CRC cells were treated with SR48692 (0, or 10 µM) 
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one day after transfection. Luciferase activity was measured 
from cell lysates using a Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI) through Sirius Luminometer 
(Berthold Detection Systems, pforzheim, germany) according 
to the manufacturers' protocols.
Transwell migration assay. Cell migration assessments 
were performed using 8.0 µm pore size Transwell filter 
inserts (Corning Inc., Corning, NY, USA) coated with 
15 µg/ml type i collagen in 24-well plates. Briefly, HCT116 
cells, serum-starved for 24 h, were trypsinized, washed twice 
and resuspended in serum-free media supplemented with 0.1% 
BSA. For replicates, equivalent cell numbers were placed in 
the upper chamber, while the lower chamber was filled with 
the same serum-free media containing SR48692 (either 0 or 
10 µM). The cells were incubated in the Transwell chambers 
for 20 h at 37˚C. After removing the non-migrated cells from 
the upper surface of the membrane, cells on the lower surface 
were fixed with methanol and stained with 0.5% crystal violet. 
Migration was determined by counting cell numbers in four 
random fields per membrane under a Nikon Eclipse 80i micro-
scope and NIS Elements software (Nikon) at x10.
Statistical analysis. Means and standard deviations for 
triplicate or quadruple samples were calculated, and graphic 
representations summarize mRNA levels of NTSR1 and 
NTSR2, number of counted cells, migration distance, IL-8 
luciferase activity and migrated cell number. Comparisons 
between groups were performed using two-sample t-test 
or analysis of variance, as indicated, with tests for pairwise 
comparison or linear trend over dose levels.
Results
Expression analysis of NTS signaling components in endog-
enous or 5-aza-CdR treated CRC cell lines. To assess NTS and 
NTSR expression in CRC cells, we performed RT-PCR analysis 
of NTS constituents in six human CRC cell lines (KM12c, 
Caco2, DLD1, HT29, HCT116 and SW480). Whereas NTSR3 
mRNA was consistently expressed in all six cell lines (Fig. 1A), 
NTSR2 expression was not observed (data not shown). Selective 
expression of NTSR1 and NTS was noted; little to no expression 
of NTSR1 was noted in KM12c, Caco2 and DLD1 cells, and 
an absence of NTS expression was detected in SW480 cells 
(Fig. 1A). Recently, we showed that promoter methylation is 
a key mechanism regulating the differential expression of 
NTSR1 and to silence NTSR2 in NET cells (16). To confirm 
whether the altered expression of NTSR1 and NTSR2 in CRC 
cells was a result of DNA methylation, we treated DLD1 and 
Caco2 cells with the DNA methyltransferase inhibitor, 5-aza-
CdR, and evaluated the expression of the NTSRs by RT-PCR 
(Fig. 1B). Treatment with 5-aza-CdR augmented the expression 
of NTSR1 and NTSR2 in DLD1 and Caco2 cells, respectively. 
To verify these results, the level of mRNA expression was also 
examined by RT-qPCR (Fig. 1C). Treatment with 5-aza-CdR 
resulted in an approximate 54-fold induction of NTSR1 expres-
sion in DLD1 and an approximate 4-fold induction in Caco2 
cells. Together, these results suggest that NTSR1 and NTSR2 
are targets of methylation in CRC cells.
Correlation between gene silencing and promoter methyla-
tion of NTSR1 and NTSR2 in CRC cells. To determine whether 
induction of NTSR1 and NTSR2 expression by 5-aza-CdR was 
due to promoter methylation, we investigated the methylation 
status of CpG islands for these genes using methylation-
specific PCR (MSP) and bisulfite sequencing. While the 
NTSR1/2 promoters were found to be almost completely 
methylated in KM12c, Caco2 and DLD1 cells, the NTSR1 
promoter in HT29, HCT116 and SW480 cells was shown to be 
unmethylated (fig. 2A). The methylation profile of the Cpg 
sites of NTSR1 was further analyzed by bisulfite sequencing 
(Fig. 2B). Consistent with the MSP data, the CpG islands of 
NTSR1 were not methylated in HT29, HCT116 and SW480 
cells. Moreover, promoter methylation of NTSR2 was noted in 
all six CRC cell lines by MSp analysis (fig. 2A) and bisulfite 
sequencing analyses (Fig. 2C). These data demonstrate that 
promoter methylation silences the NTSR1/2 genes.
Knockdown of NTSR1 represses cell growth and migration 
in CRC cells. We previously reported that inhibition of NTS 
signaling components such as NTS and NTSR1 suppressed 
tumorigenic functions in NET cells (16,18). To elucidate the 
potential oncogenic functions of NTS components in CRC 
cells, small interfering RNA (siRNA) directed against NTSR1, 
Figure 1. Analysis of NTS signaling components in endogenous or 5-aza-CdR treated CRC cell lines. (A) Expression analysis of mRNA levels for NTS, NTSRs 
and β-actin in six CRC cells by RT-PCR. (B) Expression analysis of mRNA levels for NTS components and β-actin in DLD1 and Caco2 cells treated with 0, 
2.5 or 10 µM 5-aza-CdR by RT-pCR. Media were replaced every 24 h for 4 days. (C) Quantitative RT-pCR analysis (RT-qpCR) for DLD1 and Caco2 cells 
treated with 5-aza-CdR. Presented data are the relative amounts of mRNA calculated by the ∆∆Cq method performed in quadruplicate, with standard deviation 
(SD) shown. *p<0.05 indicates a significant difference in mRNA levels between the inhibitor and vehicle (0 µM) treatments; gApDH was the internal control.
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Figure 2. Methylation analysis of NTSR1 and NTSR2 promoter regions in CRC cells. (A) MSP analysis of the NTSR1 and NTSR2 promoters in six CRC cell 
lines using primers specific for methylated (M) and unmethylated (U) DNA, respectively. (B) Bisulfite genomic sequencing of NTSR1 CpG islands in CRC 
cell lines. Each row of circles indicates the DNA sequence of an individual clone; closed and open circles represent methylated and unmethylated Cpg sites, 
respectively. Bold grey lines are candidate CpG islands detected by Methyl Primer Express Software v1.0 (Applied Biosystems). The arrows below the CpG 
islands represent sites of the primers for bisulfite sequencing (thicker) and MSp (thinner), respectively. (C) Bisulfite sequencing analysis of the 5' region of 
NTSR2 in the CRC cells; protocol and data presentation are as outlined above.
figure 3. Silencing of NTSR1 influences cell growth and migration in CRC cells. (A) Equal numbers of HCT116 (left) and HT29 (right) cells transfected with 
siRNA against non-targeting (Cont) or NTSR1 were seeded in 24-well plates. Cells were counted after 48 and 96 h incubation using a cell counter. *P<0.05 
indicates a significant difference in cell number versus Cont. (B) Analyses of mRNA by RT-pCR (left) and protein by western blot (right) for expression of 
iL-8, cyclin D1 and NTSR1 in HCT116 and HT29 cells transfected with Cont or NTSR1 siRNA. β-actin was the loading control. (C) Migration analysis by 
wound-healing assay was performed with Cont and NTSR1 knockdown HCT116 cells. Phase-contrast microscopic images (left) show Cont or NTSR1-silenced 
cells at 1 h (upper) or 22 h (bottom) after removal of the insert (dark center/cell-free zone). White lines show the cell boundary and the graph (right) provides 
quantification of the migrated distance. *p<0.05 indicates a significant difference in migration versus Cont. (D) Migration analysis with Cont and NTSR1 
knockdown HT29 cells; protocol and data presentation are as outlined in (C).
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which is inconsistently expressed among the tested cell 
lines (Fig. 1A), was used in HCT116 and HT29 cells since 
these cell lines do express the NTS transcript (Fig. 1A), and 
release NTS peptide (19). Knockdown of NTSR1 inhibited 
cell growth for 48 and 96 h in both HCT116 and HT29 cells 
compared with cells transfected with non-targeting control 
siRNA (Fig. 3A). Furthermore, silencing NTSR1 significantly 
suppressed mRNA expression of IL-8, which can be induced 
by NTS signaling (20) and is associated with tumorigenic 
functions in CRC (21) and cyclin D1, which is important for 
cell growth (18,22) (Fig. 3B, left). Protein expressions of IL-8 
and cyclin D1 were also decreased in cell lines with NTSR1 
knockdown (Fig. 3B, right). In addition to cell proliferation, 
NTSR1 activation influences cell migration and invasion 
in some cancers including breast and NET (13,16,23). On 
the basis of these studies, we next assessed the migratory 
activity of CRC cells transfected with NTSR1 siRNA using a 
wound-healing migration assay. Silencing NTSR1 suppressed 
cell migration of HCT116 cells (Fig. 3C) and HT29 cells 
(fig. 3D), respectively. Collectively, these findings suggest 
that knockdown of NTSR1 significantly inhibits the growth 
and migration of CRC cells.
SR48692, an NTSR1 antagonist, suppresses cell proliferation 
and migration of CRC cells. To further delineate the role of 
NTSR1, we examined the effect of a pharmacologic blockade of 
NTSR1 using SR48692 in HCT116 and HT29 cells. Treatment 
with SR48692 repressed proliferation in HCT116 and HT29 
cells for 48 and 96 h (Fig. 4A) and reduced both mRNA (upper 
panels) and protein expressions (lower panels) of IL-8 and 
cyclin D1 in the cell lines (fig. 4B). Additionally, SR48692 
inhibited the promoter activity of IL-8, which promotes tumor 
growth, metastasis and angiogenesis in CRC cell lines (21) 
(Fig. 4C). Moreover, HCT116 cells treated with SR48692 
showed significantly decreased cell migration compared to 
vehicle-treated control cells (fig. 4D). These results confirm 
that treatment with a selective NTSR1 antagonist inhibits cell 
growth and migration of CRC cells, and is consistent with 
results obtained with the siRNA experiments outlined above. 
These data indicate that inhibition of NTSR1, either through 
gene knockdown or receptor blockade, suppresses the growth 
and migration of CRC cells, and demonstrates a role for 
NTSR1 in CRC tumorigenesis.
Discussion
it has been reported that NTS and/or NTSR1 are over expressed 
in some types of cancers and many cancer cell lines, and that 
inhibition of NTS signaling can suppress the oncogenic activi-
ties in several cancer cell lines (10-14,16,23,24). Moreover, 
Figure 4. SR48692, an NTSR1 antagonist, decreases CRC cell growth and migration. (A) Equal numbers of HCT116 (left) and HT29 (right) cells were plated 
in 24-well plates. One day after seeding, cells were treated with 0 or 10 µM SR48692 for 48 and 96 h; cell numbers were determined using a cell counter. 
Significant difference versus vehicle (0 µM) treatments at 48 h (*) and 96 h (†) are indicated, with p<0.05. (B) RT-pCR (upper) and western blot (bottom) 
analyses show regulated expressions of iL-8 and cyclin D1 in HCT116 and HT29 cells after SR48692 treatment for 2 days. (C) graphic representation of the 
relative luciferase activity at the IL-8 promoter in HCT116 (left) and HT29 (right) cells treated with SR48692. *p<0.05 indicates a significant difference in 
iL-8 promoter activity versus vehicle treatment. (D) Migration analysis using the Boyden chamber with HCT116 cells treated with 10 µM SR48692 or vehicle 
(control) for 20 h. phase-contrast microscopic images (left) and quantification of migrated cells observed in four different fields using an inverted microscope 
(right) are shown. *p<0.05 indicates a significant difference in migrated cell number versus control.
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there is accumulating evidence that NTSR1 activation is 
linked with poor prognosis, cancer progression and a higher 
incidence of metastases in lung and breast cancers (13,14). 
However, the regulatory mechanism directing the expres-
sion of NTS pathway components in CRC cells is not 
well-delineated. One regulatory process has been proposed; 
activation of Wnt/β-catenin signaling plays an essential role 
in the upregulation of NTSR1 in CRC (25) and NTS is a 
direct target of the Wnt/β-catenin pathway in NET cells (18). 
in addition, Dong et al in our laboratory showed that promoter 
methylation contributes to the regulation of NTS expression 
in human cancer cells including colon cancer (26,27) and we 
have also recently demonstrated that promoter methylation is 
an important molecular process regulating the expression of 
NTSR1 and NTSR2 in NET cells (16). Herein, we observed 
diverse expression of NTSR1 and NTS, no expression of 
NTSR2, and consistent expression of NTSR3 in the CRC cells 
examined in this study. In particular, we speculate that the 
varied level of NTS expression (KM12c, Caco2, DLD1, HT29 
and HCT116 versus SW480 cells, Fig. 1A) is attributed to 
promoter methylation on the basis of our current result and 
previous study that DNA methylation is associated with NTS 
expression in CRC cells (27). We also found that the gene 
expression patterns for NTSR1 and NTSR2 in CRC cells are 
similar to those in NET (16) suggesting that promoter methyla-
tion of NTS signaling constituents is closely associated with 
silencing of the genes in human cancer cells.
In NTS pathway genes (especially NTSR1 and NTSR2) 
whose expression was demonstrated to be modulated by 
promoter methylation in our study, it has been reported that 
activation of NTSR1 induces cell proliferation, migration and 
invasion in a variety of cancers (8,11,24). Therefore, we evalu-
ated the role of NTSR1 on cell growth and migration in CRC 
cell lines. In previous studies, the effects of NTS-mediated 
NTSR1 activation were usually assessed through direct treat-
ment of cancer cells with NTS or an NTS agonist (11,15,23,24). 
Herein, we determined the effect of NTSR1 inhibition without 
NTS treatment on cell growth and migration in CRC cells. 
Previously, NTS expression was reported in some cancer cells 
including CRC (11-14); these findings were confirmed in our 
present study by RT-PCR analysis (Fig. 1A). In addition, our 
group identified NTS peptide secretion in CRC cell lines 
including HCT116 and HT29 (19). Analogous to our previous 
findings and current study, we find that endogenous NTS can 
exert stimulatory properties of cell growth and migration 
through NTSR1 in CRC cells through both autocrine and 
paracrine pathways.
As aforementioned, it has been reported that a higher level 
of NTSR1 expression is observed in several human cancer 
tissues such as pancreas, lung, breast, prostate, colon and NET 
and that the NTSR1 correlates with tumor progression and 
aggressiveness (10-16). These findings suggest that NTSR1 
may be a potential diagnostic biomarker and treatment target 
for these cancers. However, as noted above, NTSR1 promoter 
hypermethylation, which can lead to the gene silencing, was 
also found in lung and pancreatic cancers through genome scan-
ning or global DNA methylation profiling, and was identified as 
a predictive marker for the cancers (28-30). These intricacies 
imply that additional unrevealed adjusters or mechanisms may 
affect the level of NTSR1 expression and that further work is 
needed to clarify the detailed machinery between expression 
and silencing of NTSR1 in various types of cancer.
In conclusion, our study shows that promoter methylation 
is a key regulatory event for NTSR1 and NTSR2 expression in 
CRC cells. in addition, we confirmed that inhibition of NTSR1 
suppresses cell proliferation and migration in these cells. Our 
findings provide a rationale and incentive to explore NTSR1 as 
a therapeutic target of CRC growth and pathogenesis.
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